Dr. Lu Liangjing
吕良敬
Chief Physician; Professor; Director of the Department of Rheumatology; Doctoral Supervisor
Where they practice, who they consult.
- Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
- 25+ years in rheumatology
- English, Mandarin
What they personally lead.
Training and recognition
Leads one of China's largest SLE outpatient cohorts at Renji Hospital, which is a national clinical key specialty for rheumatology; principal investigator on multicenter Chinese trials of belimumab and the domestically developed BLyS/APRIL dual inhibitor telitacicept (泰它西普) in SLE; standing committee member of the Chinese Rheumatology Association SLE working group; contributed to the 2020 Chinese SLE diagnosis and treatment guidelines; published in Annals of the Rheumatic Diseases, Lupus, and Rheumatology
What to expect
Dr. Lu is well-suited for international patients with active SLE considering biologic add-on therapy, women planning pregnancy with lupus or antiphospholipid syndrome, and patients with refractory lupus nephritis seeking access to Chinese-developed biologics. Telitacicept is approved in China but not yet available in most Western countries — discuss long-term follow-up logistics with the team. <!-- TODO: needs second source -->
Check the public record
Look up publications, citations, and academic profile on independent platforms before reaching out.
Results are automated searches and may include other individuals with similar names.
Ask the AI or request a coordinator.
The AI can compare Lu Liangjing's background to other specialists in Shanghai. A coordinator can confirm appointment availability and English-language support.
Information is provided for reference only and may not reflect current conditions. Verify directly with the hospital before making decisions.